Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Janux Therapeutics Q4 2024 GAAP EPS $(0.36) Beats $(0.47) Estimate

Author: Benzinga Newsdesk | February 27, 2025 04:34pm
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.47) by 23.4 percent. This is a 44 percent decrease over losses of $(0.25) per share from the same period last year.

Posted In: JANX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist